Remepy

Biotechnology · Health Care
Lately:5 news stories in 90 daysFollow changes →

Facts

as of Nov 17, 2026

Redefining combination therapy by fusing traditional pharmaceuticals with clinically validated app-delivered protocols in a single, regulated prescription.

Employees
11-50estimated range
Website
remepy.com

These are the key facts about Remepy on Alion as of Nov 17, 2026. The latest round is Series A of $36M, announced in 2026.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$36MTotal raised
Series ALatest round
1Rounds and grants
Money by yearUSD, rounds and grants
2026$36M1 record
Largest rounds and grants
$36M
Sources: funding announcements, grant and company registers

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

Sep 292026
News · neurology live
Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.
Sep 162026
Press release · PRNewswire
/PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the appointment of Eran Harary, MD, as Chief Medical Officer, effective October 1, 2026....
Sep 162026
Aug 202026
News · Pulse 2.0
Remepy has raised $36 million in Series A financing to advance its pipeline of Hybrid Drugs, including global Phase III development of Hybridopa for Parkinson's disease, bringing…
Aug 132026
News · Tech Lens Media
Remepy raised $36M to advance Hybridopa into Phase III and expand its Hybrid Drug platform combining medicines with personalized AI-driven digital protocols.
Sources: the outlets named on each headline, each story once